Skip to content
10-Q

Quarterly Report

Oyster Point Pharma, Inc.

0001720725-22-000048

← back to feed
Filed
May 5, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Apr 29, 2022 26.67M sh
Shares Diluted Q1 2022 · Mar 31, 2022 26.63M sh
Shares Diluted Q1 2022 · Mar 31, 2021 25.92M sh
Capex Q1 2022 · Mar 31, 2022 $85K
Capex Q1 2022 · Mar 31, 2021 $340K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$49.71M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$16.53M
Long Term Debt Q1 2022 · Mar 31, 2022 $90.64M
Long Term Debt Q1 2022 · Dec 31, 2021 $89.82M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $143.36M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $193.37M
Cash And Equivalents Q1 2022 · Mar 31, 2021 $175.91M
Stockholders Equity Q1 2022 · Mar 31, 2022 $55.99M
Stockholders Equity Q1 2022 · Dec 31, 2021 $99.54M
Stockholders Equity Q1 2022 · Mar 31, 2021 $170.65M
Stockholders Equity Q1 2022 · Dec 31, 2020 $186.66M
Current Liabilities Q1 2022 · Mar 31, 2022 $23.03M
Current Liabilities Q1 2022 · Dec 31, 2021 $28.8M
Total Liabilities Q1 2022 · Mar 31, 2022 $120.73M
Total Liabilities Q1 2022 · Dec 31, 2021 $123.08M
Current Assets Q1 2022 · Mar 31, 2022 $167.35M
Current Assets Q1 2022 · Dec 31, 2021 $215.25M
Total Assets Q1 2022 · Mar 31, 2022 $176.72M
Total Assets Q1 2022 · Dec 31, 2021 $222.62M
Eps Diluted Q1 2022 · Mar 31, 2022 −$1.80
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.73
Eps Basic Q1 2022 · Mar 31, 2022 −$1.80
Eps Basic Q1 2022 · Mar 31, 2021 −$0.73
Sga Expense Q1 2022 · Mar 31, 2022 $12.93M
Sga Expense restated Q1 2022 · Mar 31, 2021 $8.53M
Rd Expense Q1 2022 · Mar 31, 2022 $4.68M
Rd Expense Q1 2022 · Mar 31, 2021 $5.83M
Net Income Q1 2022 · Mar 31, 2022 −$47.89M
Net Income Q1 2022 · Mar 31, 2021 −$18.91M
Operating Income Q1 2022 · Mar 31, 2022 −$42.21M
Operating Income Q1 2022 · Mar 31, 2021 −$18.92M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $336K
Cost Of Revenue Q1 2022 · Mar 31, 2021 $0
Revenue Q1 2022 · Mar 31, 2022 $2.7M
Revenue Q1 2022 · Mar 31, 2021 $0